Opinion

Video

ASH 2023 Updates on Frontline Therapies in MCL

Author(s):

Grzegorz S. Nowakowski, MD,Jennifer Crombie, MD

A panel of experts review latest data from ASH 2023 on approved and emerging therapies in frontline MCL.

Related Videos
Peter Forsyth, MD
Minoo Battiwalla, MD, MS
Leo I. Gordon, MD
Richard Kim, MD, Moffitt Cancer Center
Farrukh Awan, MD, discusses treatment considerations with the use of pirtobrutinib in previously treated patients with hematologic malignancies.
Nancy U. Lin, MD, discusses the safety data from DESTINY-Breast12 with T-DXd for HER2+ advanced/metastatic breast cancer with or without brain metastases.
Daniel DeAngelo, MD, PhD, discusses how the shift away from chemotherapy has affected the management of chronic lymphocytic leukemia.
Tiago Biachi, MD, PhD
Related Content
Dana-Farber Cancer Institute Faculty Among Highly Cited Researchers | Image Credit: © Cornflakesei - stock.adobe.com
November 21st 2024

Dana-Farber Cancer Institute Faculty Among World's Most Highly Cited Researchers for 2024

OncLive On Air
September 11th 2024

Oncology Experts Preview Top Abstracts From the 2024 ESMO Congress

BTK Inhibitors in Late-Relapse Mantle Cell Lymphoma | Image Credit: © Dr_Microbe - stock.adobe.com
November 19th 2024

Retrospective Data Show BTK Inhibitors May Be Optimal Second-Line Approach in Late-Relapse Mantle Cell Lymphoma

Narjust Florez, MD
September 5th 2024

Florez Focuses on Patient-Centered NSCLC Biomarker Testing Discussions

Bendamustine/Obinutuzumab Induction in MCL
November 18th 2024

Bendamustine/Obinutuzumab Induction Generates Responses and MRD Negativity in Treatment-Naive MCL

Natural Killer Cells in Ovarian Cancer | Image Credit: © Dr_Microbe - stock.adobe.com
November 18th 2024

First Clinical Trial of “Memory Like” Natural Killer Cells in Ovarian Cancer Opens at Dana-Farber